Clinical Trial Update: Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix Residing in UK

View source ↗

Summary

A completed post-marketing safety study evaluating the risk of spontaneous abortion in UK women exposed to Cervarix.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Human Papillomavirus Infection

Drugs mentioned

• Cervarix (human papillomavirus vaccine, bivalent)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Status: COMPLETED